Biogen Idec, Inc. (Massachusetts) Announces Availability Of FAMPYRA® In Ireland To Treat Walking Impairment In Adults With Multiple Sclerosis

Published: Jan 15, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MAIDENHEAD, England & DUBLIN--(BUSINESS WIRE)--Biogen Idec today announced that FAMPYRA® (prolonged-release fampridine tablets) has been made available in Ireland for the symptomatic treatment of walking impairment in adults with Multiple Sclerosis (MS). FAMPYRA is a prescription drug and is licensed for use in all types of the disease, including the progressive forms. FAMPYRA is available by way of retail pharmacy on a private payment basis. FAMPYRA is not currently available for reimbursement through any of the Health Service Executive’s (HSE’s) payment schemes.

Help employers find you! Check out all the jobs and post your resume.

Back to news